Loading…
5 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25,755 | 25,201 | 20,703 | 25,075 | 28,869 | 18,626 | 13,250 | 13,792 |
| EBITDA | 3,408 | 13 | 704 | 1,150 | 1,132 | 2,375 | 1,402 | 776 |
| Net profit | -1,155 | -29 | 295 | 1,121 | -193 | 1,671 | 1,486 | 942 |
| Total assets | 7,696 | 9,150 | 7,830 | 9,721 | 9,289 | 9,313 | 10,157 | 9,842 |
| n (companies reporting) | 2 | 4 | 5 | 5 | 5 | 4 | 3 | 3 |
GEL, thousands
| Company | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Medparma Plus | 3,289 | 3,481 | 3,518 | 3,769 | 5,016 | 5,008 | 4,488 | 4,916 |
| Medpoli | — | 4,004 | 6,309 | 7,013 | 7,395 | 5,096 | 4,955 | 4,660 |
| Em Pharma | — | — | 0 | 4,049 | 4,724 | 4,350 | 3,807 | 4,216 |
| Sakhalkho Aptiaki | 22,466 | 17,716 | 8,405 | 5,993 | 7,644 | 4,171 | — | — |
| Sakartvelos Parmatsevtu… | — | 0 | 2,471 | 4,252 | 4,089 | — | — | — |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Peer coverage varies by year — FY2017–FY2019, FY2022–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.